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BACKGROUND: Prolyl hydroxylation is a post-translational modification that affects the structure, stability and function of proteins
including collagen by catalysing hydroxylation of proline to hydroxyproline through action of collagen prolyl hydroxylases3 (C-P3H)
and 4 (C-P4H). Three C-P3Hs (nomenclature was amended according to approval by the HGNC symbols and names at http://
www.genenames.org/ and Entrez database at http://www.ncbi.nlm.nih.gov/gene) leucineproline-enriched proteoglycan (leprecan) 1
(Lepre1), leprecan-like 1 (Leprel1), leprecan-like 2 (Leprel2) and two paralogs Cartilage-Related Protein (CRTAP) and leprecan-like 4
(Leprel4) are found in humans. The C-P4Hs are tetrameric proteins comprising a variable a subunit, encoded by the P4HA1, P4HA2
and P4HA3 genes and a constant b subunit encoded by P4HB.
METHODS: We used RT–PCR, qPCR, pyrosequencing, methylation-specific PCR, western blotting and immunohistochemistry to
investigate expression and regulation of the C-P3H and C-P4H genes in B lymphomas and normal bone marrow.
RESULTS: C-P3H and C-P4H are downregulated in lymphoma. Down-regulation is associated with methylation in the CpG islands and
is detected in almost all common types of B-cell lymphoma, but the CpG islands are unmethylated or methylated at lower levels in
DNA isolated from normal bone marrow and lymphoblastoid cell lines. Methylation of multiple C-P3H and C-P4H genes is present in
some lymphomas, particularly Burkitt’s lymphoma.
CONCLUSIONS: Methylation of C-P3H and C-P4H is common in B lymphomas and may have utility in differentiating disease subtypes.
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Non-Hodgkin lymphomas (NHLs) are a heterogeneous group of
lymphoid neoplasms that display distinct cytogenetic and mole-
cular genetic features (Piva et al, 2010; Gutierrez-Garcia et al, 2011;
Salaverria and Siebert, 2011; Visco et al, 2012). Studies of recurrent
chromosome aberrations in NHL have provided significant insight
into genetics of lymphomagenesis. Most common translocations
are t(14;18) in follicular lymphoma (FL), t(11;14) in mantle cell
lymphoma (MCL), t(3;14) in diffuse large B-cell lymphoma
(DLBCL) and t(8;14) in Burkitt’s lymphoma (BL) (Ong and
Le Beau, 1998; Chaganti et al, 2000). In addition to structural
changes, transcriptional silencing is another major mechanism of
tumour suppressor gene inactivation in human cancer, including
haematological malignancies (Lee et al, 2010; Eberle et al, 2011). A
number of mechanistically important genes have been identified as
targets for methylation-dependent transcriptional silencing in
lymphomas, including the cyclin-dependent kinase inhibitors
CDKN2A and CDKN2B, the p53 homologue TP73, the DNA
damage-activated protein kinase DAPK and other genes with
putative tumour suppressor functions (Belaud-Rotureau et al,
2008; Guan et al, 2010; Murray et al, 2010). Using suppression
subtraction PCR, we previously identified the Polo-like kinase
PLK2 to be transcriptionally silenced in NHL, with a particularly
high frequency of methylation in BL (Syed et al, 2006). However,
epigenetic changes in some NHL types, for example FL and MCL
remain to be elucidated.
Prolyl hydroxylation is an important post-translational mod-
ification that affects the structure and function of proteins. A
major substrate of prolyl hydroxylation is collagen and appro-
priate post-translational processing of collagen requires both
C-P3H and C-P4H, respectively. Three C-P3H enzymes have been
identified in humans: leucineproline-enriched proteoglycan
(leprecan) 1 (Lepre1), leprecan-like 1 (Leprel1) and leprecan-like
2 (Leprel2) (Wassenhove-McCarthy and McCarthy, 1999); Vranka
et al, 2004). Prolyl 3-hydroxylation typically occurs in the
Gly–3Hyp–4Hyp sequence of collagen and P3H modified residues
are abundant in basement membrane collagens (Gryder et al,
1975). Initially, Leprel1 was shown to localise predominantly in
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the ER and Golgi, but more recently has been detected in tissues
rich in basement membranes and shown to participate in the
hydroxylation of type IV collagen (Jarnum et al, 2004; Tiainen et al,
2008). We have previously shown that Leprel1 and Leprel2, but not
Lepre1, are subject to methylation-dependent transcriptional
silencing in breast cancer. Further, whereas methylation in Leprel2
was also present in multiple tumour types, methylation in Leprel1
appeared specific to breast cancer as the CpGisland was
unmethylated in several other carcinomas (Shah et al, 2009). The
human genome contains two paralogs of the P3H genes, namely
Cartilage-Related Protein (CRTAP) and leprecan-like 4 (Leprel4).
Although CRTAP is not enzymatically active, it is required in vivo
for collagen prolyl 3-hydroxylation (Morello et al, 2006). The
biological importance of prolyl hydroxylation in the post-transla-
tional modification of collagen is demonstrated by the observation
that germ-line mutations in CRTAP and Lepre1 cause recessive
forms of osteogenesis imperfecta and loss or decrease of type I
collagen prolyl 3-hydroxylation (Cabral et al, 2007; Baldridge et al,
2008) and mutation in Leprel1 is associated with inherited myopia
(Mordechai et al, 2011). Prolyl 4-hydroxylation is essential for the
biosynthesis of collagens because 4-hydroxyproline residues are
critical for stability of the collagen triple helix. The human C-P4Hs
are tetrameric isoenzymes composed of two b subunits (encoded by
P4HB) and two (catalytic) a subunits. There are three different a
subunits encoded by P4HA1, P4HA2 and P4HA3. The b subunit is
identical to the protein duslphideisomerase. In contrast to the
C-P3Hs, no disorders of collagen synthesis have thus far been
associated with heritable change in genes encoding the C-P4Hs. As
well as collagen, both C-P3Hs and C-P4Hs may have additional
substrates that contain collagen-like domains.
Here, we have investigated expression and regulation of the
collagen prolyl hydroxylase genes in lymphoma.
MATERIALS AND METHODS
Cell lines and tumours
NHL cell lines and EBV-immortalised B lymphoblastoid cell lines
(LCL) were maintained in RPMI 1640 (Gibco, Invitrogen, Carlsbad,
CA, USA) medium containing 10% fetal bovine serum. The
following cell lines were used in our study:
Mantle cell lymphoma cell line: JVM2; Transformed FL cell lines:
DoHH-1, DoHH-2 and SU-DHL-4. DLBCL cell lines: CRL, DHL-4,
DHL-7, LK6; EBV ve BL: BL2, BL41, DG75, Louckes and Ramos;
EBVþ ve BL: AW Ramos, Akata 2000, MAK-I, Rael, Namalwa,
Raji, Wewack 1, P3HR1 c16 and Jijoye; EBV ve BL because of
loss of EBV: Akata 31; LCLs from peripheral blood: B301,
LCL3, X50-7, LCL-K, BMþAkata, PFþB95-8 and CRþ
B95-8. LCL from cord blood: C2þBL16.
The study received approval from the Ethics Committee of
Ioannina University Hospital, Ioannina, Greece. Formalin fixed,
paraffin-embedded tissue samples were retrieved from the archives
of the Pathology Department, University Hospital of Ioannina,
Ioannina, Greece. As control tissues, we used bone marrow (BM)
aspirates from individuals with non-malignant disease that
contained no neoplastic cells. In all cases, the diagnosis was
confirmed following review by an expert haematopathologist.
Genomic DNA was isolated by digestion in proteinase K following
xylene treatment of the tissue sections. Primary breast carcinomas
(from the Tayside Tissue Bank) and breast and ovarian carcinoma
cell lines were described previously (Shah et al, 2009).
Methylation reversal
Exponentially growing cells were treated with azacytidine (AZA;
Sigma, St Louis, MO, USA) for 5 days. Cells were split every 2 days
with the addition of fresh drug. After drug treatment, mRNA was
isolated using the RNeasy kit (Qiagen Ltd., West Sussex, UK).
Analysis of gene expression
Total RNA was extracted from exponentially growing cultured cells
using RNAzolB or Trizol. In all, 500–1000 ng of total RNA was
converted to cDNA and used for analysis of gene expression by
RT–PCR. GAPDH was used as a control gene. Primers were
designed using Primer3 software. Primer sequences for RT–PCR
were
Lepre1: Forward: 50-CTGCAGCACACACCTTCTTC-30
Reverse: 50-ACAGCTTCCTGTGGCTGTTC-30
Leprel1: Forward: 50-AATGTGTGAGGGAACTTGCCAC-30
Reverse: 50-CGGGTCAATGCTATCATCCAGC-30
Leprel2: Forward: 50-ATGCTCAGGTGGGCAATCTGTC-30
Reverse: 50-TCAAGGGCTTTGGCTTCACG-30
CRTAP: Forward: 50-GGGTTGAAGGCAAGAGGAGAAAG-30
Reverse: 50-GCTGAAGGAGAAACAGAAGGATGTG-30
Leprel4: Forward: 50-AGCACGGAGGACATGGAC-30
Reverse: 50-GGTCAAATTGGCCTCACAGT-30
P4HA1: Forward: 50-CCCTAAGGCAACTGGATGAAGG-30
Reverse: 50-ATTTTGATACCCTCCCCACGGC-30
P4HA2: Forward: 50-GGTGAAGCGGCTAAACACAGAC-30
Reverse: 50-CAGTCATCCACACTCAGCATTGC-30
P4HA3: Forward: 50-TTCAACAACCCCTGTGGCTAAC-30
Reverse: 50-GTCATCCCCTGTGAGAGAAAAGAG-30
P4HB: Forward: 50-CAAACAGTTGGCTCCCATTT-30
Reverse: 50-CCCCGTTGTAATCAATGACC-30
GAPDH: Forward: 50-TGCCTCCTGCACCACCAACT-30
Reverse: 50-CGCCTGCTTCACCACCTTC-30
Reactions were resolved on 1.2% agarose gels and visualised on
a transilluminator after staining with ethidium bromide. GAPDH
was co-amplified as a control gene using primers previously
described (Syed et al, 2006).
Total RNA was extracted from 10 mm paraffin sections of
archival lymphoma cases using commercial systems (RecoverAll
Total Nucleic Acid Isolation kit, Ambion, Carlsbad, CA, USA). For
qPCR analysis, 25 ml PCR reactions were performed using 50 ng of
cDNA obtained by reverse transcription. Amplification and
analysis were done according to the manufacturer’s protocol in
96-well plates in an ABI PRISM 7000 Sequence Detection System
(Applied Biosystems, Foster City, CA, USA) and the pre-cast
‘TaqMan Gene Expression Assays’ (Applera, https://products.
appliedbiosystems.com/). Quantification of target transcripts was
performed in comparison to the reference transcript b2 micro-
globulin (Hs99999907_m1), using the ‘delta–delta Ct method for
comparing relative expression results in real-time PCR as outlined
by PE Applied Biosystems. Western blotting for Leprel1 and
Leprel2 was done as described previously (Shah et al, 2009).
Methylation analysis
CpG islands are located in the 50 end of the Lepre1, Leprel1 and
Leprel2 genes (Shah et al, 2009). CpG islands were also identified in
the 50sequences of Leprel4, CRTAP and the P4H genes (http://
www.ebi.ac.uk/Tools/emboss/cpgplot/index.html). Genomic DNA
(1mg) was modified by sodium bisulphite as described previously
(Syed et al, 2006; Shah et al, 2009). Methylation-specific PCR (MSP)
primers for the Lepre1, Leprel1 and Leprel2 CpG islands were as
described previously (Shah et al, 2009). Primer sequences for MSP
analysis of the remaining genes were as follows:
CRTAP:
Unmethylated forward: 50-TTTTATGGGATGAGTTGATGTTGT-30
Unmethylated reverse: 50-AACTAATCTCCAAATAACCCACACT-30
Methylated forward: 50-TTTACGGGACGAGTTGATGTC-30
Methylated reverse: 50-AAACTAATCTCCAAATAACCCACG-30
Leprel4:
Unmethylated forward: 50-TGGGTATGTTTTGGAGTAGTATGA-30
Unmethylated reverse: 50-CAATTAACATAACAAAAAACCTCACT-30
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Methylated forward: 50-GTACGGGTACGTTTTGGAGTAGTAC-30
Methylated reverse: 50-ACAATTAACGTAACAAAAAACCTCG-30
P4HA1:
Unmethylated forward: 50-GGATTGTTGTAGTTGTTTGAGAAGGTTTAT-30
Unmethylated reverse: 50-ACAATCACCAAAACACTAATATAATCAAA-30
Methylated forward: 50-CGTCGTAGTCGTTCGAGAAGGTTTACG-30
Methylated reverse: 50-GCAATCGCCGAAACGCTAATATAATCG-30
P4HA2:
Unmethylated forward: 50-GTTTGTAGTTTATTGTATGTATTTTGTGT-30
Unmethylated reverse: 50-CAAATCATAACAACCTCTCCAAACACC-30
Methylated forward: 50-GTTCGTAGTTTATCGTACGTATTTCGCGT-30
Methylated reverse: 50-CGAATCGTAACGACCTCTCCAAACG-30
P4HA3:
Unmethylated forward: 50-TTGAGGTTTTTTGGTTGTTTTTATTTGTTG-30
Unmethylated reverse: 50-CTCAAAACAACACATTCTCAACACT-30
Methylated forward: 50-TTTTTCGGTCGTTTTTATTCGTCGT-30
Methylated reverse: 50-GAAACGACACGTTCTCGACGCT-30
P4HB:
Unmethylated forward: 50-TTAGGTTTGGTTTCGGATTCGGAAAC-30
Unmethylated reverse: 50-AAACAACGAACGCGAAATCCTCGAC-30
Methylated forward: 50-TTAGGTTTGGTTTTGGATTTGGAAATGT-30
Methylated reverse: 50-CTAAAAAAAACAACAAACACAAAATCCTCA-30
Methylation was also analysed quantitatively by pyrosequen-
cing. Primer sequences were as follows:
Lepre1: Forward: 50-GGGAGTGGGGAGGATAAG-30
Reverse: 50-CCTCCCTAACCTACAACTA-30
Leprel1: Forward: 50-GGGGTTGTTTTATAGTGG-30
Reverse: 50-AAATACCCCAAAACCCTC-30
Leprel2: Forward: 50-GTAGATTGTTTGATTTAGTG-30
Reverse: 50-CCACCTAATAATAAACCCTC-30
CRTAP: Forward: 50-GATGTATATAATTTATTAGGG-30
Reverse: 50-CCAACACCTAAAAAATACC-30
Leprel4: Forward: 50-CTGGAGGAAGGTGTAGG-30
Reverse: 50-TTATCTTCACCCAAAACA-30
P4HA1: Forward: 50-GGTTGTTGTGGTAATTTGGG-30
Reverse: 50-AACTAAAACCACTAAACAACC-30
P4HA2: Forward: 50-GTTTTTTTGTTTAGTTTTTGGG-30
Reverse: 50-CTCTCCCTACAACCCC-30
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Figure 1 Leprel4 and CRTAP are down-regulated by methylation in NHL. (A) RT–PCR and MSP analysis of expression and CpG island methylation of
Leprel4 and CRTAP in NHL cell lines. Expression of Leprel4, CRTAP and GAPDH was determined as described in Materials and Methods. The MSP figure
shows U and M specific reactions for the indicated NHL cell lines. Also shown is control methylated (CM) and control unmethylated (CU) genomic DNA
modified in parallel with cell line DNA samples. (B) Pyrosequencing analysis of Leprel4 and CRTAP CpG islands in NHL cell lines. The % methylation at each
analysed CpG dinucleotide is represented by the intensity of shading in the circles as shown in the figure, together with the mean % methylation for each cell
line. (C) Demethylation reactivates expression of Leprel4 and CRTAP. MAK-I and AK31 cells (Leprel4 and CRTAP CpG islands methylated) were grown
without AZA ( ) or in the presence of AZA for 24 or 48 h as indicated and expression of Leprel4 and CRTAP determined by qPCR.
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P4HA3: Forward: 50-GGTATAGTGTATTTTATTGAG-30
Reverse: 50-ACTACTAAAACTACTAAAAC-30
PCR conditions were as follows: Initial activation step at 951C
for 10min, denaturation 951C for 30 s, annealing 551C (Lepre1)/
521C (Leprel1)/541C (Leprel2)/521C (Leprel4)/511C (CRTAP)/551C
(P4HA1)/541C (P4HA2)/491C (P4HA3) for 30 s for 30 s, extension
721C for 40 s and final extension 721C for 7min. PCR was
performed for 40 cycles after which PCR products were electro-
phoresed through 2% agarose gel, and visualised using a
transilluminator. The PCR products were then analysed by
pyrosequencing using the Biotage Sample Prep kit (Diatech, Jesi,
Italy). Analysis of percentage methylation at each CpG dinucleo-
tide was performed using Pyromark ID Software (Biotage).
Placental DNA (Sigma) was used as negative control for
methylation (0% average methylation) and a commercial methy-
lated DNA (Millipore, Billerica, MA, USA) was used as positive
control (98% average methylation).
Immunohistochemistry
Expression of Leprel1 and Leprel2 was analysed by immunohis-
tochemistry (IHC) performed using standard techniques
(with antigen retrieval) on archival lymphoma cases from the
archives of the Pathology Department, University Hospital of
Ioannina, Ioannina, Greece as described above in cell lines and
tumours.
Statistics
We used descriptive statistics and Spearman’s rank correlation test
to assess the association between methylation and down-regulation
of expression. All statistical analyses were performed using Prism 5
(GraphPad software, Inc., La Jolla, CA, USA).
RESULTS
Methylation-dependent transcriptional silencing of
Leprel 4 in NHL
We first analysed expression of Leprel4 in a panel of NHL cell lines.
Leprel4 transcript was expressed in LK6, JVM2 and DHL-7 and all
LCL analysed but was undetectable in the remaining cell lines
(Figure 1A and data not shown). Inspection of Leprel4 revealed the
presence of a CpG island in the 50 sequences of the gene (http://
www.ebi.ac.uk/Tools/emboss/cpgplot/index.html), suggesting the
possibility that expression is epigenetically regulated and we
analysed the CpG island of Leprel4 in each cell line using MSP. In
the NHL cell lines lacking expression of Leprel4 mRNA, there was
methylation in the CpG island analysed but the CpG island was
unmethylated in each cell line which expressed Leprel4 mRNA
(Figure 1). To validate the MSP analysis, we further characterised
methylation in the Leprel4 CpG island using a quantitative
technique, pyrosequencing. Representative pyrograms for genes
analysed in this study are shown in Supplementary Figures 1 and 2.
There was dense methylation in the CpG island in CRL, DoHH-2
and DHL-4 (all cell lines positive by MSP), but only a low level of
methylation in JVM2 (negative by MSP) (Figure 1). Next, we
analysed methylation in a series of BL cell lines. There was
frequent methylation in the Leprel4 CpGisland, with 13/16 cell lines
showing dense methylation by pyrosequencing (Figure 1;
Tables 1A and b). Exposure to AZA reactivated expression in
MAK-I and AK31, consistent with methylation-dependent silen-
cing (Figure 1). Normal BM control DNA was negative for Leprel4
methylation in 4/4 cases (Tables 1A). Leprel4mRNA was expressed
and the CpG island uniformly unmethylated in breast and ovarian
cancer cell lines and primary breast carcinomas (Supplementary
Figure 3).
CRTAP methylation in NHL
These results prompted us to analyse expression of the Leprel4
homologue CRTAP in the same cell line panel. CRTAP mRNA was
abundantly expressed in LCL and the majority of NHL cell lines
analysed, but at lower levels in Jijoye, AK31, AK2000, Elijah,
MAK-I and BL2 (Figure 1). Like Leprel4 the 50 sequences of CRTAP
contain a CpG island. Methylation-specific PCR analysis of the
CpG island revealed dense methylation in five of the seven cell
lines with down-regulated expression, but methylation was not
detected by MSP in BL2 and Jijoye (Figure 1). To validate the MSP
analysis, we further characterised methylation in the CRTAP CpG
Table 1A Frequency of methylation of CpG islands of C-P3H and C-P4H genes in lymphoma
Lepre1 Leprel1 Leprel2 Leprel4 CRTAP P4HB P4HA1 P4HA2 P4HA3
Cell lines
Non-BL 0/4 4/4 2/4 1/4 0/4 0/4 0/4 0/4 4/4
BL 0/15 16/16 12/16 13/16 4/16 0/15 0/15 9/15 15/15
LCL 0/10 0/10 1/10 1/6 0/6 0/10 0/10 0/10 2/10
Clinical cases
DLBCL 2/100 86/100 8/100 10/100 16/100 0/36 0/36 15/100 48/100
HIV DLBCL 0/8 6/8 2/8 3/8 2/8 0/8 0/8 1/8 3/8
FL 2/11 9/11 0/11 0/11 0/11 0/11 0/11 0/11 2/11
MCL 1/10 4/10 1/10 0/10 1/10 0/10 0/10 0/10 1/10
MZL 1/28 14/28 0/28 0/28 0/28 0/28 0/28 0/28 4/28
BL 1/9 8/9 9/9 4/9 1/9 0/9 0/9 8/9 9/9
HIV BL 0/4 4/4 4/4 2/4 1/4 0/4 0/4 4/4 4/4
Normal 0/4a 0/4b 0/4b 0/4a 0/4a 0/4a 0/4a 0/4a 0/4a
Abbreviations: BL¼ Burkitt’s lymphoma; DLBCL¼ diffuse large B-cell lymphoma; FL¼ follicular lymphoma; MCL¼mantle cell lymphoma; MZL¼marginal zone lymphoma;
MSP¼methylation-specific PCR. aDetermined by MSP. bDetermined by pyrosequencing.
Table 1B Sensitivity and specificity of analysis of C-P3H and C-P4H genes
in diagnosis of BL vs DLBCL
Gene Leprel1 Leprel2 P4HA2 P4HA3
Sensitivity 0.92 1.0 0.92 1.0
Specificity 0.54 0.93 0.87 0.68
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island using pyrosequencing. Methylation in LCL was uniformly
low, typically 2–5% at each analysed CG (see for example BM
Akata, Figure 1). We did not find evidence of methylation in
CRTAP in the other NHL cell lines (DLBCL, FL and MCL) by either
MSP or pyrosequencing (Figure 1; Table 1A). Exposure to
AZA reactivated expression in MAK-I and AK31, consistent
with methylation-dependent silencing (Figure 1). The CRTAP
CpG island was unmethylated in breast carcinoma cell lines and
ovarian carcinoma cell lines and primary breast carcinomas
(Supplementary Figure 3).
Leprel1 and Leprel2 silencing in NHL cell lines
Leprel4 and CRTAP have three paralogs in the human genome
Lepre1, Leprel1 and Leprel2, each of which has a CpG island (Shah
et al, 2009). RT–PCR revealed expression of Leprel1mRNA in each
LCL, with undetectable expression in all BL analysed (Figure 2)
and in each of the four non-BL NHL cell lines (data not shown).
Western blotting was consistent with RT–PCR (Figure 2). Leprel2
mRNA was undetectable by RT–PCR in the majority of BL cell
lines (Figure 2) but was detectable in the four non-BL NHL cell
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lines (data not shown). AZA reactivated expression of Leprel1 and
Leprel2 mRNA in DG75 and Ramos, consistent with methylation-
dependent silencing and western blotting confirmed increased
Leprel2 in Ramos cells treated with AZA (Figure 2). We performed
pyrosequencing in the panel of NHL cell lines to analyse
methylation in each CpG island (Figure 2). The Leprel1 CpGisland
was methylated to a high degree in all NHL cell lines analysed,
whereas Leprel2 CpG island was methylated to a high degree in the
majority of BL cell lines but to a lower extent in the non-BL NHL
cell lines (Figure 2). Methylation in both CpG islands was low in
LCLs (Figure 2). There was an inverse correlation between
expression of both Leprel1 and Leprel2 and methylation of their
CpG islands (Figure 2). As seen with Leprel4 and CRTAP, there was
also a good correlation between methylation detected by
pyrosequencing and MSP (Figure 2). Lepre1 was expressed and
the CpG island unmethylated in all analysed lymphoma cell lines
(Supplementary Figure 4).
Specific C-P4H genes are silenced by methylation in NHL
cell lines
The frequent methylation of the C-P3H genes in NHL prompted us
to also analyse expression of the C-P4H genes in the same panel of
cell lines. The mRNA of P4HA1, P4HA2 and P4HB was abundantly
expressed in each of the LCL tested (Figure 3). P4HA1 and P4HB
were expressed in all BL cell lines at levels comparable to the LCL
but the mRNA of P4HA2 was down-regulated in many of the BL
cell lines (Figure 3). P4HA3 was expressed at low levels in all BL
cell lines but was detectable using qPCR and was down-regulated
in all BL cell lines analysed (Figure 3). We tested using
pyrosequencing whether absence of expression was associated
with aberrant methylation in the CpG islands of each C-P4H gene.
Methylation was low in the CpG island of each gene in LCLs
(Figure 3). Consistent with expression results, the P4HA1 and
P4HB CpG islands were uniformly unmethylated. The CpG island
of P4HA2 was methylated to a high degree in all of the BL
except DG75 and Louckes and there was a good correlation
between methylation of and expression of P4HA2 (as assessed
by RT–PCR) and methylation (Figure 3). The CpG island of
P4HA3 was densely methylated in all cell lines (Figure 3). Together
these results imply that expression of P4HA2 and P4HA3 is
silenced by methylation in BL cell lines. In the non-BL NHL cell
lines, the CpG islands of P4HB, P4HA1 and P4HA2 were
unmethylated, but the P4HA3 CpG island was, as in BL, uniformly
methylated (Figure 4).
Methylation of multiple P3H and P4H genes in clinical
cases
Our cell line studies showed that some of the C-P3H and C-P4H
genes are down-regulated by methylation in B lymphomas. We
therefore analysed methylation in the CpG island of each gene in a
clinical series comprising all common types of B lymphomas,
including BL, DLBCL, FL, MCL and MZL (Table 1A). As control
tissues, we used BM aspirates from individuals (with non-
neoplastic diagnoses), confirmed on histopathology to contain
no malignant cells. To fully validate our MSP assays, we initially
analysed a small series of cases by both pyrosequencing and MSP
and this showed an excellent correlation between the two
methodologies (Figure 5A). We also confirmed that methylation
is associated with transcriptional down-regulation and this was the
case (see Figure 5B for representative scatter plots for Leprel1 and
Leprel2).
We then proceeded to analyse the clinical cases using the
validated MSP assays (for representative assays see Figure 6; for
summary of data see Table 1A and Supplementary Figure 5).
Methylation was not detected in any of the nine analysed genes in
the normal BM controls. Leprel4 was methylated exclusively in
high-grade lymphomas, the highest frequency being in BL.
Similarly, CRTAP was methylated predominantly in high-grade
B301
LCL3
LCL-K
CR B95.8
BL2
BL41
AK2000
AW Ramos
DG75
AK31
MAK-I
P3HR1
Jijoye
Namalwa
Raji
Rael
Wewack
Loukes
P4HA1 P4HA2 P4HA3
1 432 5 61 432 5 61 432 5 6 7
GAPDH 
P4HA1
P4HA2
AK
31
BL
2
BL
41
D
G
75
LO
UC
KE
S
R
AM
O
S
AK
20
00
Jjo
ye
M
AK
-I
N
AM
AL
W
A
P3
HR
1 
c1
6
R
AE
L
R
AJ
I
W
EW
AC
K
B3
01
BM
 +
 A
KA
TA
LC
L-
3
PF
 B
95
.8
C2
 +
 B
L1
6
C2
 +
 O
ba
ji
LC
L-
K
X-
50
-7
0
0.5
1
1.5
AK
31 BL
2
BL
41
D
G
75
LO
UC
KE
S
R
AM
O
S
AK
20
00
JI
JO
YE
M
AK
-I
N
AM
AL
W
A
P3
H
R
1c
16
R
AE
L
R
AJ
I
W
EW
CK
B3
01
LC
L3
LC
L-
K
R
el
at
iv
e 
P4
H
A3
 m
R
N
A
0–5%     6–10% 11–20% 21–50% 51–100%
A
B
CR
 B
95
.8
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lymphomas with the highest frequency in DLBCL, although a
single case of MCL showed methylation. Leprel1 was clearly the
most frequently methylated of the C-P3H genes, with methylation
in the Leprel1 CpG island detected in 86/100 (86%) of DLBCL and
9/11 (82%) of FL. Leprel2 methylation was infrequent and was
detected only in DLBCL (at low frequency) and in BL (at high
frequency) but not in other lymphoma types. Although methyla-
tion in the CpG island of Lepre1 was not detected in NHL cell lines,
we nonetheless observed methylation in all lymphoma types, albeit
at low frequencies, in the clinical series (Table 1A). In the case of
the P4H genes, we did not detect methylation in P4HA1 or P4HB in
any lymphoma analysed, consistent with analysis of cell lines.
P4HA2 was methylated predominantly in BL, whereas P4HA3 was
methylated to a high degree in all types of NHL and BL (Table 1A).
To seek evidence that CpG island methylation does indeed result in
reduced protein expression, we performed IHC for Leprel1 and
Leprel2 (Figure 6B). In these studies, we observed down-regulation
of both proteins in all common B lymphoma types, consistent with
qPCR and methylation analyses, confirming that transcriptional
silencing is associated with reduced or absent protein expression
in lymphoma.
Analysis of C-P3H and C-P4H genes discriminates DLBCL
from BL
Inspection of the combined data set (Table 1A; Supplementary
Figure 5) showed that Leprel1 and P4HA3 are methylated at high
frequency in the majority of high-grade NHL, both in cell lines and
in clinical cases of lymphoma, whereas P4HA2 and Leprel2 are
methylated predominantly in BL and less frequently in DLBCL. We
constructed ROC curves to address the possibility that methylation
analysis of specific C-P3H and C-P4H genes facilitates discrimina-
tion between (i) NHL and LCL (ii) BL and DLBCL. In cell lines,
methylation of Leprel1, Leprel2 and P4HA3 clearly discriminated
between NHL and LCL with high sensitivity and specificity but for
P4HA2 the sensitivity was lower, consistent with lower frequency
of methylation in non-BL lymphomas (Figure 7). In clinical
lymphomas, methylation of Leprel2 and P4HA2 was a sensitive and
specific discriminator between BL and DLBCL (Figure 7). We
further assessed MSP results to determine whether non-quantita-
tive analysis of methylation can also distinguish BL from DLBCL.
Using MSP, sensitivity and specificity for both Leprel2 and P4HA2
were similar to values obtained from pyrosequencing (Table 1B).
Together, these results from two independent techniques suggest
that methylation profiling of the CpG islands of Leprel2 and P4HA2
BL and DLBCL can be useful in distinguishing between BL and
DLBCL. Finally, to further extend these observations, we asked
whether immunohistochemical analysis of Leprel2 discriminates
DLBCL from BL. Consistent with methylation analysis, expression
of Leprel2 was absent or greatly down-regulated in BL at a
significantly higher frequency than in DLBC (Po0.05).
DISCUSSION
We show that expression of the C-P3H and C-P4H collagen prolyl
hydroxylases is epigenetically downregulated in NHL cell lines and
primary lymphomas. Our data is the first demonstration of
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epigenetic silencing of the C-P3H and C-P4H genes in lymphoid
neoplasia and to the best of our knowledge the first study
describing epigenetic changes in the C-P4H genes in human
cancer. Our study of the C-P3H and C-P4H genes was prompted by
initial identification of Leprel4 as a novel epigenetically regulated
gene in lymphoma. This led us to investigate four paralogous
C-P3H genes in the human genome (CRTAP, Lepre1, Leprel1
and Leprel2) and the C-P4H genes P4HB, P4HA1, P4HA2 and
P4HA3, all of which encode proteins with functions in collagen
biosynthesis. We demonstrate methylation-dependent transcrip-
tional silencing of specific members of each gene family in B-cell
lymphoma cell lines and primary lymphomas.
In the case of the C-P3H family members, Leprel1 was silenced at
high frequency in all lymphoma types, with lower methylation
frequencies in the CpG islands of each of the other C-P3H genes
aside from BL in which we observed simultaneous silencing of
Leprel1, Leprel2, Leprel4 and CRTAP in a high proportion of cases
(both sporadic and HIV-associated). In previous work, we showed
that Leprel2 is silenced in numerous epithelial tumour types, but
silencing of Leprel1 was restricted to breast cancer with a strong
preference for oestrogen receptor positive carcinomas (Shah et al,
2009). We did not detect methylation in the CpG islands of Leprel4
or CRTAP in breast and ovarian cancer cell lines or in primary
breast cancers, suggesting that methylation in these genes is
specific for haematological neoplasia. It is striking therefore that
Leprel1 is transcriptionally silenced in the majority of B
lymphomas irrespective of subtype. Imuunohistochemistry con-
firmed down-regulation of Leprel1 and Leprel2 (albeit with
different frequencies) in clinical lymphoma cases.
In the case of the C-P4H family, we detected CpG island
methylation only in P4HA2 and P4HA3, methylation never being
seen either in P4HA1 or in P4HB (encoding the b subunit of the
C-P4H tetramer). Of note, whereas the P4HA3 CpG island was
methylated in a high proportion of lymphomas of all types, that of
P4HA2 was methylated predominantly in BL and there was
simultaneous methylation of P4HA2 and P4HA3 in many cases
of BL. This parallels the situation with the C-P3H genes with
Leprel1 and Leprel2, which are co-silenced at high frequency in BL.
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It remains to be determined whether this reflects differences
between P4HA2 and P4HA3 in terms of substrate specificity or
affinity.
Previous studies have linked germ-line mutations in Lepre1 and
CRTAP to rare forms of the collagen disorder osteogenesis
imperfecta (Morello et al, 2006; Cabral et al, 2007; Baldridge
et al, 2008), mutations resulting in reduced 3-hydroxylation of the
a chain of type I collagen. It is an interesting hypothesis that
transcriptional silencing of the C-P3H and C-P4H genes may
contribute to lymphomagenesis as a result of aberrant collagen
biosynthesis and/or post-translational modification causing base-
ment membrane malformation or other collagen abnormalities
which promote neoplasia. Alternatively, failure of prolyl hydro-
xylation of one or more of the other identified substrates for these
proteins could contribute to neoplasia in cells lacking specific
C-P3H and C-P4H. A third possibility is that P3H and P4H have
direct growth inhibitory properties. This has been directly
demonstrated for Lepre1, Leprel1 and Leprel2 (Kaul et al, 2000;
Shah et al, 2009). Further, mice lacking both CRTAP alleles exhibit
increased proliferation in some tissues, also consistent with an
anti-proliferative function (Baldridge et al, 2010). Resolution of
these hypotheses will require detailed mechanistic studies.
Even with modern histopathology, immunoprofiling and
molecular genetics, it is on occasion challenging to differentiate
between BL and DLBCL (de Leval and Hasserjian, 2009). This is of
major clinical importance because first-line chemotherapy for the
two lymphoma subtypes is very different. Differences in methyla-
tion frequency between BL and DLBCL, especially in Leprel2 and
P4HA2, led us to address the possible utility of these genes as
biomarkers to differentiate between the lymphoma types. We show
that analysis of CpG island methylation in both Leprel2 and P4HA2
discriminates between BL and DLBCL with high sensitivity and
specificity. In preliminary studies, we showed using IHC that
analysis of Leprel2 expression in BL and DLBCL may also have
biomarker utility. Clearly, larger numbers of cases will require
analysis in order to independently verify these observations.
In conclusion, we report the identification of C-P3H and C-P4H
as novel transcriptionally silenced gene families in B lymphomas.
Additional studies are required in order to validate the initial
findings presented in this report and to further elucidate the
possible role of transcriptional silencing of the C-P3H and C-P4H
genes in lymphomagenesis.
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